Manufacturing Split Genentech / Roche & Novartis
Manufacturing Location & Sales – Genentech / Roche & Novartis ($ in 000′s) *
| Avastin Sales |
2010 Q4 | 2011 Q1 | 2011 Q2 | 2011 Q3 | 2011 Q4 | 2012 Q1 |
|---|---|---|---|---|---|---|
| US Made & Sold |
800,139 | 708,539 | 719,967 | 688,966 | 684,878 | 652,824 |
| US Made & ex-US Sold |
415,576 | 580,981 | 548,710 | 587,975 | 375,830 | 448,037 |
| ex-US Made & Sold |
430,503 | 307,941 | 314,028 | 304,155 | 409,286 | 401,896 |
| Total | 1,646,218 | 1,597,461 | 1,582,705 | 1,581,095 | 1,469,994 | 1,502,757 |
| US Made & Sold |
49% | 44% | 45% | 44% | 47% | 43% |
| US Made & ex-US Sold |
25% | 36% | 35% | 37% | 26% | 30% |
| ex-US Made & Sold |
26% | 19% | 20% | 19% | 28% | 27% |
| Herceptin Sales |
2010 Q4 | 2011 Q1 | 2011 Q2 | 2011 Q3 | 2011 Q4 | 2012 Q1 |
|---|---|---|---|---|---|---|
| US Made & Sold |
416,611 | 409,854 | 442,903 | 445,395 | 453,168 | 456,920 |
| US Made & ex-US Sold |
425,303 | 423,053 | 642,670 | 495,086 | 612,908 | 523,353 |
| ex-US Made & Sold |
567,396 | 558,661 | 474,402 | 702,416 | 366,695 | 534,982 |
| Total | 1,409,310 | 1,391,568 | 1,559,975 | 1,642,898 | 1,432,771 | 1,515,255 |
| US Made & Sold |
30% | 29% | 28% | 27% | 32% | 30% |
| US Made & ex-US Sold |
30% | 30% | 41% | 30% | 43% | 35% |
| ex-US Made & Sold |
40% | 40% | 30% | 43% | 26% | 35% |
| Lucentis Sales |
2010 Q4 | 2011 Q1 | 2011 Q2 | 2011 Q3 | 2011 Q4 | 2012 Q1 |
|---|---|---|---|---|---|---|
| US Made & Sold |
360,911 | 378,451 | 409,674 | 422,335 | 428,884 | 433,428 |
| US Made & ex-US Sold |
443,773 | 509,307 | 533,745 | 630,474 | 646,131 | 645,665 |
| ex-US Made & Sold |
- | - | - | - | - | - |
| Total | 804,684 | 887,757 | 943,418 | 1,052,809 | 1,075,015 | 1,079,092 |
| US Made & Sold |
45% | 43% | 43% | 40% | 40% | 40% |
| US Made & ex-US Sold |
55% | 57% | 57% | 60% | 60% | 60% |
| ex-US Made & Sold |
0% | 0% | 0% | 0% | 0% | 0% |
| Xolair Sales |
2010 Q4 | 2011 Q1 | 2011 Q2 | 2011 Q3 | 2011 Q4 | 2012 Q1 |
|---|---|---|---|---|---|---|
| US Made & Sold |
170,001 | 164,621 | 167,608 | 184,837 | 188,728 | 185,505 |
| US Made & ex-US Sold |
- | - | - | - | - | - |
| ex-US Made & Sold |
93,388 | 103,133 | 110,034 | 126,037 | 126,184 | 124,729 |
| Total | 263,389 | 267,754 | 277,642 | 310,874 | 314,911 | 310,234 |
| US Made & Sold |
65% | 61% | 60% | 59% | 60% | 60% |
| US Made & ex-US Sold |
0% | 0% | 0% | 0% | 0% | 0% |
| ex-US Made & Sold |
35% | 39% | 40% | 41% | 40% | 40% |
| Total Sales |
2010 Q4 | 2011 Q1 | 2011 Q2 | 2011 Q3 | 2011 Q4 | 2012 Q1 |
|---|---|---|---|---|---|---|
| US Made & Sold |
1,747,662 | 1,661,465 | 1,740,152 | 1,741,534 | 1,755,657 | 1,728,678 |
| US Made & ex-US Sold |
1,284,652 | 1,513,340 | 1,725,125 | 1,713,535 | 1,634,869 | 1,617,054 |
| ex-US Made & Sold |
1,091,287 | 969,735 | 898,464 | 1,132,608 | 902,165 | 1,061,607 |
| Total | 4,123,601 | 4,144,540 | 4,363,741 | 4,587,677 | 4,292,691 | 4,407,339 |
| US Made & Sold |
42% | 40% | 40% | 38% | 41% | 39% |
| US Made & ex-US Sold |
31% | 37% | 40% | 37% | 38% | 37% |
| ex-US Made & Sold |
26% | 23% | 21% | 25% | 21% | 24% |
* As reported to PDL by its licensees
Totals may not sum due to rounding

